Index 2011 performance summary 23 Managing risk 129 Market definitions 209 Accounting policies 146, 194 Medicines 3, 4, 10, 32, 35, 56 Acquisitions and disposals 170 Neuroscience 67 Annual general meeting 112, 208 Nomination and Governance Committee 105, 106, 109 Aptium Oncology 22 Oncology 70 Articles of association 206, 208 Operating profit 1, 4, 23, 85, 91, 151 Astra Tech 22 Operational overview 5 Audit Committee 107 Other investments 148, 160 Biologics 16, 18, 19 Outsourcing 21, 135 Board 99 Patents see Intellectual Property Branches 111 Patient safety 53 Business background and results overview 83 People 19, 21, 25, 40, 176 Capitalisation 90 Pipeline 5, 19, 21, 24, 31, 32, 57, 130, 199 Cardiovascular 58 Political donations 112 Cash and cash equivalents 148, 160 Portfolio Investment Board PIB 110 Chairmans statement 6 Post-retirement benefits 96, 138, 165 Chief Executive Officers review 8 Pricing 18, 37 Commitments and contingent liabilities 181 Principal risks and uncertainties 129 Company history 203, 208 Product revenue information 150 Competition 15, 133 Property, plant and equipment 148, 156 Compliance and Group Internal Audit 43, 110 Provisions for liabilities and charges 88, 93, 164 Consolidated statement of cash flows 145 Regulatory requirements 17 Consolidated statement of changes in equity 144 Related party transactions 205 Consolidated statement of comprehensive income 142 Relations with shareholders 106 Consolidated statement of financial position 143 Remuneration Committee 113 Corporate Responsibility see Responsible Business Research and Development 16, 30, 147, 151 Directors interest in shares 125 Reserves 169 Directors remuneration 113 Respiratory & Inflammation 73 Directors responsibility statement 140 Responsible Business 47 Dividends 6, 90, 170, 205 Rest of World 79, 209 Earnings per ordinary share 4, 154 Restructuring 22, 151 Emerging markets 16, 36, 77, 80, 132, 209 Results of operations 2010 91 Employee costs and share plans for employees 176 Results of operations 2011 85 Environmental sustainability 53 Safety, health and wellbeing 54 Established markets 16, 36, 77, 78, 209 Sales and Marketing 36 Ethics 50, 51 Sales by therapy area 56 Finance income and expense 152 Science Committee 109 Financial instruments 148, 161 Segment information 154 Financial position 2010 93 Senior Executive Team SET 102, 110 Financial position 2011 88 Share capital 170, 196, 203 Financial risk management 93, 171 Share repurchase 90, 111, 170, 196 Financial summary 1 Statutory and other information 190 Gastrointestinal 62 Strategy 19 Glossary 209 Subsidiaries 191 Goodwill 88, 93, 96, 147, 157 Supply and Manufacturing 38 Group financial record 198 Taxation 89, 93, 97, 138, 147, 152, 189 Group financial statements 139 Taxation information for shareholders 206 Growth drivers 15 Trade and other payables 88, 93, 148, 164 Independent auditors report 141, 192 Trade and other receivables 88, 93, 148, 160 Infection 64 Trade marks inside back cover Inflammation see Respiratory & Inflammation Transactions with directors 124 Intangible assets 88, 93, 95, 96, 147, 158 UK corporate governance 103 Intellectual Property 34, 131, 132, 133 UK Corporate Governance Code 103 Interest-bearing loans and borrowings 148, 161, 173, 195 US 78, 209 Inventories 148, 160 US corporate governance 109 Key performance indicators 23 World pharmaceutical markets 16 Leases 148, 190 Litigation 96, 133, 136, 149, 183, 184, 194, 197 212 Index AstraZeneca Annual Report and Form 20-F Information 2011 Important information for readers of this Annual Report Statements of competitive position, growth rates and sales In this Annual Report, except as otherwise stated, market information regarding the Cautionary statement regarding forward-looking statements position of our business or products relative to its or their competition is based upon The purpose of this Annual Report is to provide information to the members of the published statistical sales data for the 12 months ended 30 September 2011 obtained Company.
The Company and its Directors, employees, agents and advisors do not from IMS Health, a leading supplier of statistical data to the pharmaceutical industry.
accept or assume responsibility to any other person to whom this Annual Report is For the US, dispensed new or total prescription data and audited sales data are shown or into whose hands it may come and any such responsibility or liability is taken, respectively, from IMS Health National Prescription Audit and IMS National expressly disclaimed.
In order, among other things, to utilise the safe harbour Sales Perspectives for the 12 months ended 31 December 2011: such data is not provisions of the US Private Securities Litigation Reform Act of 1995 and the UK adjusted for Medicaid and similar state rebates.
Except as otherwise stated, these Companies Act 2006, we are providing the following cautionary statement: This market share and industry data from IMS Health have been derived by comparing our Annual Report contains certain forward-looking statements with respect to the sales revenue to competitors and total market sales revenues for that period.
Except operations, performance and financial condition of the Group.
Forward-looking as otherwise stated, growth rates are given at CER.
For the purposes of this Annual statements are statements relating to the future which are based on information Report, unless otherwise stated, references to the world pharmaceutical market or available at the time such statements are made, including information relating to risks similar phrases are to the 53 countries contained in the IMS Health MIDAS Quantum and uncertainties.
Although we believe that the forward-looking statements in this database, which amounted to approximately 96% in value of the countries audited Annual Report are based on reasonable assumptions, the matters discussed in the by IMS Health.
forward-looking statements may be influenced by factors that could cause actual outcomes and results to be materially different from those expressed or implied by AstraZeneca websites these statements.
The forward-looking statements reflect knowledge and information Information on or accessible through our websites, including astrazeneca.
com, available at the date of the preparation of this Annual Report and the Company .
com, does not form part of and is not undertakes no obligation to update these forward-looking statements.
We identify incorporated into this Annual Report.
the forward-looking statements by using the words anticipates, believes, expects, External third party websites intends and similar expressions in such statements.
Important factors that could Information on or accessible through any third party or external website does not cause actual results to differ materially from those contained in forward-looking form part of and is not incorporated into this Annual Report.
statements, certain of which are beyond our control, include, among other things, those factors identified in the Principal risks and uncertainties section from Figures page 130 of this Annual Report.
Nothing in this Annual Report should be construed Figures in parentheses in tables and in the Financial Statements are used to represent as a profit forecast.
Inclusion of reported performance, Core financial measures and constant exchange rate growth rates AstraZenecas determination of non-GAAP measures together with our presentation of them within our financial information may differ from similarly titled non-GAAP measures of other companies.
connectsusall Trade marks Trade marks of the AstraZeneca group of companies appear throughout this Annual Report in italics.
AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trade marks of the AstraZeneca group of companies.
Trade marks of companies other than AstraZeneca Improving health is one of the toughest challenges facing the appear with a sign and include: Abraxane, a trade mark of Abraxis BioScience, LLC.
: Cubicin, a trade mark of Cubist Pharmaceuticals, Inc. : CytoFab, a trade mark of Protherics world today.
As a global biopharmaceutical company, AstraZeneca TM Inc. : Kombiglyze XR and Komboglyze, trade marks of Bristol-Myers Squibb Company: Lipitor, a trade mark of Pfizer Ireland Pharmaceuticals: Onglyza, a trade mark of Bristol-Myers has a key contribution to make by providing innovative medicines TM Squibb Company: Ranmark, a trade mark of Daiichi Sankyo Company Limited: and Teflaro, a trade mark of Forest Laboratories, Inc. for some of the worlds most serious diseases.
Designed and produced by Board photography Marcus Lyon We know that if we are to deliver medicines that people really need and value, we cannot Cover image by Iain Crockart, Gorky Park, Moscow do it in isolation.
We work closely with all our stakeholders to understand their needs and This report is printed on Heaven 42 which is FSC certified virgin fibre.
The pulp is a mix, partly bleached using an Elemental Chlorine Free ECF challenges.
We are committed to acting with integrity and high ethical standards in everything process and partly bleached using a Totally Chlorine Free process.
Printed in the UK by Pureprint using its alcofree and pureprint environmental we do and our goal is always to improve health for patients and bring benefit for our printing technology, and vegetable inks were used throughout.
Both manufacturing mill and the printer are stakeholders, our business and society.
registered to the Environmental Management System ISO14001 and are Forest Stewardship Council chain-of-custody certified.
AstraZeneca Annual Report and Form 20-F Information 2011 Contact information Registered office and Investor relations Registrar US Depositary corporate headquarters Email: ir@astrazeneca.
com Equiniti Limited JPMorgan Chase & Co AstraZeneca PLC Aspect House PO Box 64504 2 Kingdom Street UK: as above Spencer Road St Paul London W2 6BD Lancing MN 55164-0504 UK Sweden: West Sussex BN99 6DA US Tel: 44 0 20 7604 8000 Investor Relations UK Tel toll free in the US : Fax: 44 0 20 7604 8151 AstraZeneca AB Tel freephone in the UK : 888 697 8018 SE-151 85 Sdertlje 0800 389 1580 Tel outside the US : Sweden Tel outside the UK : 1 651 453 2128 Tel: 46 0 8 553 260 00 44 0 121 415 7033 Email: jpmorgan.
com Fax: 46 0 8 553 290 00 Swedish Central Securities US: Depository Investor Relations Euroclear Sweden AB AstraZeneca Pharmaceuticals LP PO Box 191 1800 Concord Pike SE-101 23 Stockholm PO Box 15437 Sweden Wilmington Tel: 46 0 8 402 9000 fide 19850-5437 US Tel: 1 302 886 3000 Fax: 1 302 886 2972 This Annual Report is also available on our website, astrazeneca.
com annualreport2011 health AstraZeneca Annual Report and Form 20-F Information 2011
